The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.
Anais Laforest
No relevant relationships to disclose
Thomas Aparicio
No relevant relationships to disclose
Aziz Zaanan
No relevant relationships to disclose
Fabio pittella Silva
No relevant relationships to disclose
Audrey Didelot
No relevant relationships to disclose
Aurelien Desbeaux
No relevant relationships to disclose
Delphine Le Corre
No relevant relationships to disclose
Leonor Benhaim
No relevant relationships to disclose
Karine Pallier
No relevant relationships to disclose
Daniela Ellen Aust
No relevant relationships to disclose
Steffen Pistorius
No relevant relationships to disclose
Helene Blons
No relevant relationships to disclose
Magali Svrcek
No relevant relationships to disclose
Pierre Laurent-Puig
Honoraria - Amgen; Merck Serono